Evotec Subsidiary Just - Evotec Biologics Expands Development and Manufacturing Agreement with ABL for Broadly Neutralising Antibodies Against HIV, Financial Terms Undisclosed

Author: Benzinga Newsdesk | February 07, 2024 03:03am

Evotec SE ((Frankfurt Stock Exchange: EVT, MDAX/TecDAX, OTC:EVOTF, NASDAQ:EVO) today announced that its Seattle-based subsidiary Just - Evotec Biologics, Inc. has expanded its relationship with Advanced BioScience Laboratories, Inc. ("ABL"), a global contract development and manufacturing organisation ("CDMO") serving the US Government and biopharmaceutical industry. The expansion is under a new contract funded entirely by Federal funds under an indefinite delivery/indefinite quantity ("IDIQ") contract awarded to ABL from National Institute of Allergy and Infectious Disease ("NIAID"), National Institutes of Health ("NIH"), Department of Health and Human Services, ("DHHS") under Contract No. HHSN272201700010I/ 75N93023F00001.

The new agreement builds on previous collaborations between Just - Evotec Biologics and ABL to design highly efficient manufacturing processes for broadly neutralising antibodies ("bNAbs") against HIV. Under the expanded relationship, Just - Evotec Biologics will develop a third bNAb and perform large-scale cGMP manufacturing campaigns for both this bNAb and a previously developed bNAb against HIV for a Phase I clinical study. Just - Evotec Biologics will also provide release and stability testing services.

Posted In: EVO